Azacitidine and Quizartinib for Blood Cancer
Phase 1/2
58
about 7.4 years
18+
1 site in TX
What this study is about
This trial is testing the safety and best dose of quizartinib when combined with azacitidine in people with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm who have FLT3 or CBL mutations. The goal is to see if this combination treatment can help control these blood cancers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Azacitidine
- 2.Take Quizartinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
azacitidine, quizartinib
injection, subcutaneous, oral (Oral Tablet)
Primary: Duration of response, Incidence of adverse events (AEs), Overall response rate, Overall survival, Relapse-free survival
Oncology